PanGenomic Health, Inc. Class A (NARA) AI Stock Analysis

• Market Cap: C$7.44M
• Dividend Yield: N/A
• Average Volume (3M): 110.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.38
• Revenue Growth: N/A
• EPS Growth: 81.01%
• Country: CA
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.11
• Shares Outstanding: 14,046,870
• 10 Day Avg. Volume: 77,322
• 30 Day Avg. Volume: 110,395
• PEG Ratio: >-0.01
• Price to Book (P/B): >-0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.60 ▲(16.67% Upside)

The score is held down primarily by very weak financial performance (no revenue, ongoing losses/cash burn, and negative equity). Technicals also remain bearish with the stock below major moving averages and negative MACD. Corporate events provide some support via financing and product/distribution initiatives, but do not offset the underlying profitability and balance-sheet challenges.

Positive Factors

Strategic Partnerships

The exclusive distribution agreement with Ayla BioScience enhances PanGenomic's market presence in the natural health sector, potentially boosting product offerings and market positioning in personalized medicine.

Product Innovation

The launch of a DNA testing program on the Nara.Care AI platform strengthens PanGenomic's position in personalized wellness, expanding its market reach and enhancing stakeholder engagement.

Financial Flexibility

The $2 million private placement provides critical working capital and reduces debt, improving financial flexibility and supporting operational stability.

Negative Factors

Lack of Revenue

The absence of recorded revenue indicates an unproven business model, raising concerns about the company's ability to generate sustainable income and achieve profitability.

Negative Cash Flow

Persistent negative cash flow highlights reliance on external funding, posing a risk to long-term financial health and operational sustainability.

Negative Shareholders' Equity

Negative shareholders' equity limits financial flexibility and indicates accumulated deficits, posing a significant risk to the company's financial stability.

PanGenomic Health, Inc. Class A Business Overview & Revenue Model

Company Description

Pangenomic Health Inc., a precision health company, develops a self-care digital platform to deliver personalized and evidence-based information about natural treatments to support mental health. It develops the Nara App, a mobile app that provides consumers with a knowledge base tailored to an individual's unique user profile; and the PlantGx Platform, a digital therapeutics clinic platform that provides health practitioners with access to user health data enabled from the Nara App by the patient and to receive patient referrals. The company was formerly known as Zetta Capital Corp. and changed its name to PanGenomic Health Inc. in December 2021. Pangenomic Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.

How the Company Makes Money

PanGenomic Health, Inc. generates revenue primarily through subscription services to its digital health platform. Users pay for access to personalized recommendations and insights based on their genomic data. Additionally, the company may earn revenue through partnerships with healthcare providers and wellness brands, offering them access to its platform for broader distribution and integration of personalized health solutions. The company may also monetize aggregated and anonymized data insights for research and development purposes in collaboration with academic and commercial partners.

PanGenomic Health, Inc. Class A Financial Statement Overview

Summary

PanGenomic Health, Inc. is in a precarious financial position with zero revenue, increasing net losses, negative equity, and reliance on external financing, indicating significant challenges in achieving financial stability and growth.

Income Statement

PanGenomic Health, Inc. has consistently reported zero revenue across all periods. The company has faced increasing net losses, with the latest TTM (Trailing-Twelve-Months) net income at -3.51 million, reflecting an unsustainable financial trajectory. The absence of revenue growth and consistent negative profit margins indicate severe challenges in achieving profitability.

Balance Sheet

The balance sheet shows negative stockholders' equity and a concerning equity deficit in the latest period, indicating that liabilities far exceed assets. Although there is no debt to equity ratio due to negative equity, the company has reduced its liabilities compared to previous years. However, the financial instability is evident with negative equity and low asset values.

Cash Flow

The cash flow statement reveals significant negative free cash flow, indicating cash outflows exceed inflows. The operating cash flow is negative, further stressing financial health. While financing cash flow has been positive, driven by external funding, reliance on external capital is not sustainable long-term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-471.00	―	-681.43K	-11.11K	-2.13K	0.00
EBITDA	-3.37M	―	-2.71M	-3.57M	-847.50K	-1.81K
Net Income	-3.41M	-3.80K	-2.97M	-20.35M	-2.65M	-139.99K
Balance Sheet
Total Assets	270.90K	39.16K	71.48K	504.14K	2.58M	147.22K
Cash, Cash Equivalents and Short-Term Investments	82.16K	1.31K	12.56K	88.53K	1.35M	38.23K
Total Debt	0.00	0.00	964.75K	101.77K	0.00	27.50K
Total Liabilities	2.04M	2.44M	2.22M	719.25K	334.45K	136.27K
Stockholders Equity	-1.77M	-2.41M	-2.14M	-215.11K	2.24M	10.95K
Cash Flow
Free Cash Flow	-1.70M	-58.25K	-1.57M	-2.79M	-1.07M	-37.52K
Operating Cash Flow	-1.70M	-58.25K	-1.57M	-2.78M	-1.06M	-37.52K
Investing Cash Flow	0.00	0.00	-3.14K	-52.13K	-604.91K	-100.00K
Financing Cash Flow	1.75M	47.00K	1.50M	1.57M	2.97M	173.50K

PanGenomic Health, Inc. Class A Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.51
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NARA, the sentiment is Negative. The current price of 0.51 is below the 20-day moving average (MA) of 0.60, below the 50-day MA of 0.79, and below the 200-day MA of 1.04, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 43.63 is Neutral, neither overbought nor oversold. The STOCH value of 31.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:NARA.

PanGenomic Health, Inc. Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NDAT	43 Neutral	C$619.91K	-2.68	-40.64%	―	-100.00%	65.85%
NARA	42 Neutral	C$7.44M	-1.61	―	―	―	81.01%
NEWU	42 Neutral	C$866.33K	-0.23	―	―	―	―
TMED	38 Underperform	C$755.08K	-0.23	―	―	―	-1188.37%

PanGenomic Health, Inc. Class A Corporate Events

PanGenomic Health Launches $2 Million Private Placement to Bolster Working Capital and Reduce Debt

PanGenomic Health Inc. has announced a non-brokered private placement of up to 4,000,000 units at $0.50 per unit, for total gross proceeds and debt settlement of up to $2 million. Each unit comprises one Class A common share and one warrant exercisable at $0.75 for two years, with the funds earmarked for general working capital and settling outstanding indebtedness, including amounts owed to directors and officers. The offering, subject to a four-month-plus-one-day hold and closing no earlier than five business days after the announcement, will see participation from company insiders and is structured to qualify for exemptions from formal valuation and minority shareholder approval requirements under Canadian securities rules, underscoring a balance between near-term balance sheet support and adherence to related-party transaction safeguards for existing shareholders.

PanGenomic Health Enters Agreement with Ayla BioScience for Exclusive Distribution

PanGenomic Health Inc. has signed a non-binding letter of intent with Ayla BioScience to establish an exclusive distribution agreement and a share purchase agreement. This collaboration will allow PanGenomic to distribute Ayla’s Zeotech products in Canada as part of a personalized medicine solution, potentially enhancing its market presence in the natural health sector. The agreement also includes an equity investment by PanGenomic in Ayla BioScience, indicating a strategic move to strengthen its product offerings and market positioning.

PanGenomic Health Launches DNA Testing Program on Nara.Care AI Platform

PanGenomic Health has launched a DNA testing program as part of its Nara.Care AI platform, targeting health-conscious consumers in Canada with plans to expand to the United States. The Agenta branded DNA testing kits will provide data to the Nara.Care AI platform, offering personalized insights into various health aspects while ensuring data privacy. This initiative strengthens PanGenomic Health’s position in personalized wellness, potentially impacting its market reach and stakeholder engagement.